ArticleRespiratory research2022
Prevalence, characteristics, and risk of exacerbation in young patients with chronic obstructive pulmonary disease.
Article in Respiratory research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Development of a daily predictive model for the exacerbation of chronic obstructive pulmonary disease.Scientific reports · 2023Trial
- Exposure to tobacco smoke, concurrent short-term symptoms of respiratory, allergic, cardiovascular morbidities and health-services use among young adults in Kuwait.BMC health services research · 2026Observational
- Evaluation of Clinical Characteristics and Lung Function Trajectories in Young COPD Patients Within the General Population.International journal of chronic obstructive pulmonary disease · 2026Article
- Chronic Obstructive Pulmonary Disease in Never-Smokers-A Distinct Entity Within the COPD Spectrum.Life (Basel, Switzerland) · 2025Review
- Epidemiological trends and risk factors of chronic obstructive pulmonary disease in young individuals based on the 2021 global burden of disease data (1990-2021).BMC pulmonary medicine · 2025Article
- Risk of acute exacerbation of chronic obstructive pulmonary disease after COVID-19 recovery: a nationwide population-based cohort study.Respiratory research · 2025Article
- Comprehensive appraisal of lung function in young COPD patients: a single center observational study.BMC pulmonary medicine · 2024Observational
- Risk factors of acute exacerbation and disease progression in young patients with COPD.BMJ open respiratory research · 2024Observational
- Prevalence, risk factors, and mortality of COPD in young people in the USA: results from a population-based retrospective cohort.BMJ open respiratory research · 2023Article
- Association of Smoking and Respiratory Disease History with Pancreatic Pathologies Requiring Surgical Resection.Cancers · 2023Article
- COPD Risk Factor Profiles in General Population and Referred Patients: Potential Etiotypes.International journal of chronic obstructive pulmonary disease · 2023Observational
- Effect of smoking on the development of chronic obstructive pulmonary disease in young individuals: a nationwide cohort study.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveEarly identification of chronic obstructive pulmonary disease (COPD) in young individuals could be beneficial to attempt preventive interventions. The objective of this study was to investigate clinical features and outcomes of young individuals with COPD from the general population cohort.
methodsWe included individuals from the Korean National Health and Nutrition Examination Survey (KNHANES) with spirometry and identifiable smoking status. Young subjects with COPD were defined as aged between 40 and 50 years and had baseline forced expiratory volume in 1 s [FEV
resultsAmong 2236 individuals aged between 40 and 50 years, 95 (4.2%) had COPD, including 36 who were never-smokers and 59 who were ever-smokers. Approximately 98% of COPD subjects had mild to moderate airflow limitation. Inhaler treatment was given to only 6.3% patients in the COPD group. The risk of exacerbation for a 3-year period was analyzed using the never-smoker, non-COPD group as a comparator. Hazards ratio for exacerbation was 1.60 (95% confidence interval [CI] 0.18-14.20) in the never-smoker COPD group and 1.94 (95% CI 0.31-12.07) in the ever-smoker COPD group of young subjects. COPD related medical costs were not significantly different between non-COPD and COPD groups of young individuals.
conclusionsThe risk of exacerbation showed an increasing trend in COPD patients regardless of smoking status compared to non-COPD. More attention to early identification and provision of preventive measures are needed to reduce disease progression and improve outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.